Ross Osborn
Stock Analyst at Cantor Fitzgerald
(1.94)
# 3,146
Out of 4,966 analysts
116
Total ratings
30.84%
Success rate
-4.34%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORGO Organogenesis Holdings | Maintains: Overweight | $7 → $9 | $5.15 | +74.76% | 4 | Aug 8, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Neutral | $92 → $95 | $95.37 | -0.38% | 2 | Aug 6, 2025 | |
| CVRX CVRx, Inc. | Reiterates: Overweight | $11 | $7.85 | +40.13% | 3 | Aug 5, 2025 | |
| SIBN SI-BONE | Reiterates: Overweight | $25 | $16.67 | +49.97% | 10 | Aug 5, 2025 | |
| MDXG MiMedx Group | Maintains: Overweight | $11 → $12 | $7.10 | +69.01% | 5 | Jul 31, 2025 | |
| BVS Bioventus | Initiates: Overweight | $12 | $7.40 | +62.16% | 1 | Jul 7, 2025 | |
| XGN Exagen | Maintains: Overweight | $8 → $7 | $9.86 | -29.01% | 6 | May 15, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $2 | $1.26 | +58.73% | 6 | May 15, 2025 | |
| NPCE NeuroPace | Reiterates: Overweight | $17 | $9.15 | +85.79% | 6 | May 14, 2025 | |
| NNOX Nano-X Imaging | Maintains: Overweight | $12 → $9 | $3.87 | +132.56% | 11 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $46 | $33.66 | +36.66% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $2.28 | +250.88% | 10 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $16.14 | +48.70% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.31 | +205.34% | 4 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $9 | $7.62 | +18.19% | 7 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $4.02 | +123.88% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $4.34 | +383.87% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $6.24 | +156.41% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $1.31 | +167.18% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.69 | +262.32% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.68 | - | 7 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8.61 | $0.49 | +1,674.89% | 2 | Aug 18, 2023 |
Organogenesis Holdings
Aug 8, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $5.15
Upside: +74.76%
LeMaitre Vascular
Aug 6, 2025
Maintains: Neutral
Price Target: $92 → $95
Current: $95.37
Upside: -0.38%
CVRx, Inc.
Aug 5, 2025
Reiterates: Overweight
Price Target: $11
Current: $7.85
Upside: +40.13%
SI-BONE
Aug 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $16.67
Upside: +49.97%
MiMedx Group
Jul 31, 2025
Maintains: Overweight
Price Target: $11 → $12
Current: $7.10
Upside: +69.01%
Bioventus
Jul 7, 2025
Initiates: Overweight
Price Target: $12
Current: $7.40
Upside: +62.16%
Exagen
May 15, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $9.86
Upside: -29.01%
Lucid Diagnostics
May 15, 2025
Reiterates: Overweight
Price Target: $2
Current: $1.26
Upside: +58.73%
NeuroPace
May 14, 2025
Reiterates: Overweight
Price Target: $17
Current: $9.15
Upside: +85.79%
Nano-X Imaging
Apr 1, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $3.87
Upside: +132.56%
Mar 26, 2025
Reiterates: Overweight
Price Target: $46
Current: $33.66
Upside: +36.66%
Mar 7, 2025
Reiterates: Overweight
Price Target: $8
Current: $2.28
Upside: +250.88%
Mar 5, 2025
Reiterates: Overweight
Price Target: $24
Current: $16.14
Upside: +48.70%
Feb 21, 2025
Reiterates: Overweight
Price Target: $4
Current: $1.31
Upside: +205.34%
Jan 16, 2025
Reiterates: Overweight
Price Target: $9
Current: $7.62
Upside: +18.19%
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $4.02
Upside: +123.88%
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $4.34
Upside: +383.87%
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $6.24
Upside: +156.41%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $1.31
Upside: +167.18%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.69
Upside: +262.32%
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $1.68
Upside: -
Aug 18, 2023
Reiterates: Neutral
Price Target: $8.61
Current: $0.49
Upside: +1,674.89%